Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Curis, Inc

  • Jim Dentzer, Curis, Inc

Curis is a biotechnology company focused on the development and commercialization of innovative cancer therapeutics including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis also collaborates with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, the TIM3/PDL1 antagonist CA-327, and the IRAK4 kinase inhibitor, CA-4948. CA-170 is undergoing Phase 1 testing in patients with advanced solid tumors and lymphomas, and Phase 2 testing in India conducted by Aurigene. CA-4948 is currently in a Phase 1 trial in patients with NHL. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

  • Date:Tuesday, February 12
  • Time:10:30 AM - 10:45 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23334
  • Goal for Presentation:Raise awareness of novel oncology therapies that could dramatically impact patient lives.
  • Company Website:Curis, inc
  • Company HQ City:Lexington
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Ticker:CRIS
  • Exchange:NASDAQ
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Fimepinostat
  • Development Phase of Primary Product:Phase I
Speakers
Jim Dentzer
Curis, Inc
Back